ValuEngine lowered shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a hold rating to a sell rating in a research report sent to investors on Friday morning.
Other analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Trillium Therapeutics from a hold rating to a buy rating and set a $12.00 price objective for the company in a report on Thursday, November 23rd. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Trillium Therapeutics in a report on Thursday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Trillium Therapeutics currently has a consensus rating of Buy and an average price target of $13.33.
Shares of Trillium Therapeutics (TRIL) opened at $7.55 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. Trillium Therapeutics has a 1 year low of $4.15 and a 1 year high of $13.30.
WARNING: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/12/18/trillium-therapeutics-tril-cut-to-sell-at-valuengine.html.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.